Precursor B-cell lymphoblastic leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The three cases studied were diagnosed as B-ALL based on the expression of CD10, CD20, CD22, CD34, and CD79a by leukemic blasts.
|
27018867 |
2017 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Six of the patients with ZNF384 gene rearrangements had precursor B cell ALL with a CD10- immunophenotype and myeloid-associated antigens.
|
27392123 |
2016 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Normal karyotype CALLA-positive adult pre-B ALL: dismal outcome with chemotherapy for patients with loss/gain of ABL1 and/or BCR FISH signals.
|
23098889 |
2013 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Studies here respond to two long-standing questions: Are human "pre/pro-B" CD34(+)CD10(-)CD19(+) and "common lymphoid progenitor (CLP)/early-B" CD34(+)CD10(+)CD19(-) alternate precursors to "pro-B" CD34(+)CD19(+)CD10(+) cells, and do the pro-B cells that arise from these progenitors belong to the same or distinct B-cell development pathways?
|
20231472 |
2010 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Persistence of TEL-AML1 fusion gene as minimal residual disease has no additive prognostic value in CD 10 positive B-acute lymphoblastic leukemia: a FISH study.
|
18928518 |
2008 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The striking similarities between the two CD10- ALL subsets imply that CD10- pre-B ALL variants may represent pro-B ALL cases that maintained the propensity to rearrange and express their immunoglobulin heavy chain rather than actual pre-B ALL forms transformed at this later stage of B-cell differentiation.
|
16707593 |
2006 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data identify CD10- cytoplasmic immunoglobulin-positive pre-B ALL as a rare (2.2%) but distinct immuno-subtype of adult ALL that is characterized by a high MLL rearrangement rate and a worse outcome.
|
16123216 |
2005 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
All t-ALL cases had a pro-B (CD10-negative) immunophenotype with significantly higher expression of CD15 and CD65, compared to the de novo CD10-positive ALL cases.
|
12764373 |
2003 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
To elucidate the biologic and clinical heterogeneity of adult pro-B acute lymphoblastic leukemia (ALL) (ie, terminal deoxynucletidyl-transferase-positive[TdT+], CD19+, CD10-, surface immunoglobulin-negative [SIg-]), we evaluated 66 patients enrolled in the Italian multicentric Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) 0496 study between October 1996 and December 1999.
|
12791662 |
2003 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this prospective study, samples from 478 patients with CD10(+) B-cell precursor ALL (c-ALL and pre-B ALL) underwent BCR-ABL reverse transcription-polymerase chain reaction (RT-PCR) analysis with double testing of positive samples.
|
11861265 |
2002 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The predominant expression of Ik-6, which is the result of post-transcription dysregulation, is characteristic of adult pre-B ALL, especially CD10(+) pre-B ALL.
|
12094252 |
2002 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In contrast to pro-B leukemia cells, pre-pre-B leukemia cells from children with CD19(+)CD10(+) common B-lineage ALL and EBV-transformed B-cell lines from healthy volunteers expressed wild-type Syk coding sequences.
|
11494125 |
2001 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We report a case of CD15(+), CD10(-) ALL of early pre-B-cell origin defined by morphologic testing and FCI with the t(4;11) abnormality.
|
11520279 |
2001 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
None of the CD34(+)Lin(-) hematopoietic stem cell progenitors or the CD34(+)CD19(+) (pro-B) or the CD19(+)CD10(+) (pre-B/immature B cells) B-cell progenitors expressed CCR6.
|
11001880 |
2000 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Chromosomal translocation was identified in 24 (36.4%) of the ALL patients, 17 of whom had recurrent translocations including 10 with CD10+ B-precursor ALL [4 with t(9;22), 5 with t(1;19), and 1 infant with t(8;14)(q24;q11)], one neonate with CD10- early pre-B ALL with t(4;11), three B-cell cases with t(8;14), and three T-cell cases [2 with t(11;19)(q23;p13), and 1 (11;14)(p13;q11)].One B-precursor patient had dic (9;12).
|
10870310 |
2000 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results show that the t(12;21)(p13;q22)+ ALLs display a higher intensity of CD10 (P = 0.0016) and HLADR (P = 0.005) expression together with lower levels of the CD20 (P = 0.01), CD45 (P = 0.01), CD135 (P = 0.003) and CD34 (P = 0.03) antigens as compared to the t(12;21) cases.
|
10914546 |
2000 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conclude that several of the clinical and laboratory prognostic factors, which are used reliably for B-precursor ALL, are much less predictive in T-ALL (ie age, WBC, consensus risk group, hyperdiploidy, presence of trans- locations and CALLA expression).
|
10557041 |
1999 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In contrast to childhood acute lymphoblastic leukemia (ALL), the cell-biological features, clinical characteristics, and treatment outcome of CD10(-) pro-B ALL have not yet been determined in larger series of adult patients.
|
9731046 |
1998 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Of BCR/ABL-positive patients, 83% had early pre-B ALL, one patient had pre-T ALL, while half of the BCR/ABL-negative patients had early pre-B ALL, 18% had CD10-negative pro-B ALL and 21% were pre-T.
|
9369422 |
1997 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The 63 cases positive for the TEL/AML1 chimeric products ranged in age between 1 and 12 years, and all but one showed CD10 and pre-B immunophenotype.
|
9226156 |
1997 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
All reported patients had CD10+ pre-B-cell All, and achieved remission, as was the case for our four pediatric dic(9;20) patients.
|
8976366 |
1996 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The most predominant CD10-positive pre-B-cell type, corresponding to a precursor B-cell neoplasm, frequently involves the head and neck.
|
8534767 |
1995 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In contrast, only two patients from a group of 67 common (CD19/CD10+, cylgM/sIgM-) and pre-B ALLs (CD19/cylgM+, CD10 +/-, sIgM-) showed ALL1-AF4 mRNA.
|
7949140 |
1994 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The induction of CD10 on a pre-B leukemia cell line occurs with progression of the disease in scid mice.
|
7692193 |
1993 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Of these, 42 children with a common/pre-B phenotype (CD19/CD10-positive) were studied specifically to assess CD10 antigen density.
|
1465029 |
1992 |